Trial Profile
A Phase II Clinical Trial Evaluating Combination Therapy Using DCVax-L (Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen) and Nivolumab (an Anti-PD-1 Antibody) for Subjects With Recurrent Glioblastoma Multiforme
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary) ; Nivolumab (Primary)
- Indications Glioblastoma; Gliosarcoma; Oligodendroglioma
- Focus Adverse reactions; Therapeutic Use
- 08 Aug 2019 Status changed from Suspended to withdrawn prior to enrolment.
- 05 Aug 2019 Status changed from Not yet recruiting to Suspended .
- 02 Aug 2019 Planned End Date changed from 1 Jun 2022 to 1 Dec 2022.